Trial reportBlood2020
Glucocorticoid-induced eosinopenia results from CXCR4-dependent bone marrow migration.
Trial report in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02798523 (Genomic Response of Human Immune and Non-Immune Cells to Glucocorticoids), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Genomic Response of Human Immune and Non-Immune Cells to Glucocorticoids
Who cites it
30 citing papers in PubMed, 41 citations in OpenAlex.
- Effect of Methyl Gallate on Physiological and Gut Microbiota-Associated Responses Following a Single Intramuscular Administration of Tylosin in Weaned Piglets.Pathogens (Basel, Switzerland) · 2026Article
- The Airway Epithelial Barrier in Childhood Asthma: A Central Player in Glucocorticoid Therapy, Resistance, and Severe Asthma.Pediatric discovery · 2026Review
- Differential regulation of type 2 immunity by glucocorticoids.BMB reports · 2026Review
- Glucocorticoids suppress early lung inflammation and impair control of SARS-CoV-2 in non-human primates.PloS one · 2026Article
- Social Housing of Postoperative Animals to Support Animal Welfare.Journal of the American Association for Laboratory Animal Science : JAALAS · 2026Review
- Ischemic stroke complicated by intracerebral hemorrhage in patients with hypereosinophilic syndrome: a case series.Therapeutic advances in neurological disorders · 2026Article
- Baseline Blood Eosinophil Count and 28-Day in-Hospital Mortality in ICU-Admitted Patients with AECOPD: A Cohort Study with External Validation.International journal of chronic obstructive pulmonary disease · 2026Article
- Clinical Profiles and Mortality-Associated Risk Factors in Patients with Acute Kidney Injury from Atlixco, Puebla, Mexico.Diagnostics (Basel, Switzerland) · 2025Article
- Type I Interferon-Related Gene Expression and Laboratory Abnormalities in Acute Infection Are Associated with Long COVID Symptom Burden.Journal of clinical medicine · 2025Article
- Eosinophilic Myocarditis Treated with IL-5 Blockade: An Integrated Case Report and Literature Review.Journal of clinical medicine · 2025Review
- Zirconium-89-Oxine Cell Tracking by PET Reveals Preferential Monocyte Recruitment to Cancer and Inflammation over Macrophages.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Endogenous glucocorticoids and human immunity: Time to revisit old dogmas.Seminars in immunology · 2025Review
- Pathobiology and Regulation of Eosinophils, Mast Cells, and Basophils in Allergic Asthma.Immunological reviews · 2025Review
- Intracellular Protein Binding of Zr-89 Oxine Cell Labeling for PET Cell Tracking Studies.Pharmaceutics · 2025Article
- In vivo tracking of ex-vivo-generatedMolecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Non-Malignant Granulocyte and Monocyte Disorders: An Update.British journal of biomedical science · 2025Review
- High rates of mood disorders in patients with chronic idiopathic eosinopenia.Brain, behavior, & immunity - health · 2024Article
- Shedding light onto the immunometabolic effects of glucocorticoids.Nature reviews. Rheumatology · 2024Article
- Immune Response Dynamics and Biomarkers in COVID-19 Patients.International journal of molecular sciences · 2024Article
- Cebp1 and Cebpβ transcriptional axis controls eosinophilopoiesis in zebrafish.Nature communications · 2024Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 4 institutions in 2 countries.
Funding
Abstract
Glucocorticoids are considered first-line therapy in a variety of eosinophilic disorders. They lead to a transient, profound decrease in circulating human eosinophils within hours of administration. The phenomenon of glucocorticoid-induced eosinopenia has been the basis for the use of glucocorticoids in eosinophilic disorders, and it has intrigued clinicians for 7 decades, yet its mechanism remains unexplained. To investigate, we first studied the response of circulating eosinophils to in vivo glucocorticoid administration in 3 species and found that the response in rhesus macaques, but not in mice, closely resembled that in humans. We then developed an isolation technique to purify rhesus macaque eosinophils from peripheral blood and performed live tracking of zirconium-89-oxine-labeled eosinophils by serial positron emission tomography/computed tomography imaging, before and after administration of glucocorticoids. Glucocorticoids induced rapid bone marrow homing of eosinophils. The kinetics of glucocorticoid-induced eosinopenia and bone marrow migration were consistent with those of the induction of the glucocorticoid-responsive chemokine receptor CXCR4, and selective blockade of CXCR4 reduced or eliminated the early glucocorticoid-induced reduction in blood eosinophils. Our results indicate that glucocorticoid-induced eosinopenia results from CXCR4-dependent migration of eosinophils to the bone marrow. These findings provide insight into the mechanism of action of glucocorticoids in eosinophilic disorders, with implications for the study of glucocorticoid resistance and the development of more targeted therapies. The human study was registered at ClinicalTrials.gov as #NCT02798523.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.